Vanda Pharma’s Bysanti Wins FDA Approval, Launch Set for Q3 2026
FDA approval of Bysanti grants Vanda’s new oral treatment first-line therapy status for acute manic or mixed episodes in bipolar I and schizophrenia, with commercial launch slated for Q3 2026. Vanda expects Bysanti exclusivity through 2044 and leverages Fanapt’s $33.2 million Q4 2025 sales (+25% YoY) for bioequivalence data.
1. FDA Approval of Bysanti
The FDA has approved Bysanti (milsaperidone) as a first-line oral therapy for acute manic or mixed episodes in adults with bipolar I disorder and for schizophrenia, marking a key expansion of Vanda’s psychiatric treatment portfolio.
2. Commercial Outlook and Exclusivity
Vanda plans to introduce Bysanti to the market in Q3 2026 and expects marketing exclusivity protections to extend until 2044, positioning the company for long‐term revenue generation.
3. Bioequivalence and Fanapt Data
Clinical studies demonstrated Bysanti’s bioequivalence to iloperidone, allowing Vanda to leverage existing safety and efficacy data from Fanapt, which posted $33.2 million in net product sales in Q4 2025, up 25% year‐over‐year.
4. Ongoing Clinical Studies
Vanda is also investigating Bysanti as a treatment for major depressive disorder, with pivotal clinical trials scheduled to conclude by the end of 2026 to assess broader therapeutic applications.